The phase II ELAINEII trial (NCT04432454) is evaluating the combination of lasofoxifene with abemaciclib in advanced or metastatic HR+/HER2− BC patients with an ESR1 mutation who had disease progression on first and/or second lines of treatment, such as ET plus CDK4/6i [226]. The gene discussed is CDK4; the disease is breast cancer.